Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
KDNY.US

Chinook (KDNY) Trial Results Manipulation Case

  • In May 2023, Muddy Waters accused Chinook and AbbVie of manipulating trial results for lead product candidate, Atrasentan.
  • On it, $KDNY fell 7%, losing $100M+ shareholder value.
  • Investors may have reasons to suspect Chinook of unlawful biz practices, which consequently led to their losses.
On May 16, 2023, Muddy Waters Research in its report alleged that Chinook’s (KDNY) lead product candidate, Atrasentan, “is harmful to patients’ cardiovascular health,” and that “AbbVie and Chinook seem to have systemically manipulated research findings and presentation on atrasentan to obscure these trial results.”

On this news, $KDNY fell 7% and lost over $100 million of its market capitalization, damaging shareholders.

Considering the information, investors might have grounds to suspect that Chinook and accountables manipulated trial results figures, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
16 May 2023
Collecting participants…
Created by Stan Vick, Scout

Chinook Therapeutics Inc

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clini...

    Ticker
    KDNY.US
    ISIN
    US16961L1061
    CIK
    1435049
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    400 Fairview Avenue North, Seattle, WA, United States, 98109